May 13, 2026 07:03AM
Apr 21, 2026 08:03AM
Apr 21, 2026 08:03AM
Apr 1, 2026 04:30PM
Apr 1, 2026 04:30PM
Mar 16, 2026 06:03AM
Feb 13, 2026 08:04AM Alto Neuroscience completes enrollment in phase 2 schizophrenia study
Feb 13, 2026 08:04AM
Nov 17, 2025 05:35AM
Nov 12, 2025 07:57AM
Oct 24, 2025 06:49AM
Oct 20, 2025 10:59AM
Oct 20, 2025 07:03AM
Oct 20, 2025 07:03AM Alto Neuroscience Announces $50 Million Private Placement Financing
Oct 20, 2025 07:01AM
Oct 20, 2025 07:01AM
Oct 3, 2025 07:34AM
Oct 3, 2025 07:34AM
Sep 22, 2025 10:02AM
Jul 28, 2025 10:00AM
Jul 27, 2025 09:58AM Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): G
Jun 26, 2025 07:33AM
Jun 26, 2025 07:33AM
May 14, 2025 04:10PM
Apr 28, 2025 08:03AM
Sep 10, 2024 06:30AM
Sep 9, 2024 03:36PM
Aug 13, 2024 04:05PM Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

322,203 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All